Biogen Inc. (NASDAQ:BIIB)’s recent partnership with City Therapeutics, Inc. to develop RNAi therapies for central nervous ...

Biogen (NasdaqGS:BIIB) recently announced a collaboration with City Therapeutics, Inc. to develop RNAi therapies for central nervous system diseases, contributing to a 6% share price increase over the ...

Biogen ( NASDAQ: BIIB) and City Therapeutics signed a collaboration to develop novel RNA interference ( (RNAi)) therapies ...

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the September 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to pay ...

We recently published a list of 15 Small-Cap Healthcare Stocks Hedge Funds Are Buying. In this article, we are going to take ...

Eli Lilly (LLY) stock in focus as the company beats Biogen (BIIB) to win regulatory nod in Australia for first ...

Biotech major Biogen (Nasdaq: BIIB) and fellow Cambridge, USA-based City Therapeutics, today announced a strategic ...

The stock's fall snapped a four-day winning streak.

Biogen BIIB reported first-quarter 2025 adjusted earnings per share (EPS) of $3.02, which missed the Zacks Consensus Estimate of $3.32. Total revenues in the first quarter came in at $2.43 billion ...

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against other small-cap healthcare stocks hedge funds are buying. The U.S. healthcare sector has performed ...

In a report released today, Geoff Meacham from Citi maintained a Hold rating on Biogen ( BIIB – Research Report ), with a price target of $125.00. The company’s shares closed yesterday at $123.16.